Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FPI-2505
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FPI-2505 is a targeted alpha therapy (TAT) radiopharmaceutical developed by Fusion Pharmaceuticals (now a subsidiary of AstraZeneca). It consists of a small molecule ligand that specifically targets Fibroblast Activation Protein (FAP), conjugated to the alpha-emitting radioisotope Actinium-225 (225Ac). FAP is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of various solid tumors, including lung, colorectal, and pancreatic cancers, while showing limited expression in normal tissues. By targeting FAP, FPI-2505 delivers potent alpha radiation directly to the tumor site, inducing complex double-stranded DNA breaks and cell death in both the CAFs and adjacent malignant cells via the bystander effect. The drug is currently being evaluated in Phase 1 clinical trials for patients with FAP-expressing solid tumors.
- Other names
- [225Ac]-FPI-2505
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on FPI-2505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FPI-2505.